Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors
November 17 2021 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
the appointment of Jane Tiller, MBChB, FRCPsych, to its board of
directors.
"We are thrilled to further strengthen the deep
expertise of our Board with the addition of Dr. Tiller. Jane brings
knowledge across multiple therapeutic areas including neuroscience,
and a deep understanding and successful track record in strategy
and execution in global clinical development and medical affairs,"
stated Kevin R. Lind, Longboard’s President and Chief Executive
Officer. "These attributes will be invaluable as we advance and
expand our robust pipeline and continue to build a world-class
team."
Dr. Tiller currently serves as Chief Medical
Officer of Neumora Therapeutics, a position she has held since
Neumora acquired BlackThorn Therapeutics, where she had served as
Chief Medical Officer. Prior to BlackThorn, Dr. Tiller was Head of
Medical European Markets, Australia and Canada at Bristol-Myers
Squibb (BMS), where she oversaw all medical functions for her
territories. During her tenure at BMS, Dr. Tiller also served as
Vice President of Global Medical for neuroscience, virology and
immunoscience, and as Vice President, Full Development Gamma
Secretase for BMS' Alzheimer’s program. Previously, she held
positions of increasing responsibility at Cephalon, including as
Vice President, Clinical Research, CNS/Pain, where she was
responsible for all clinical development activities of programs for
schizophrenia, bipolar disorder, anxiety and sleep disorders. Prior
to joining industry, Dr. Tiller was Clinical Director at the
Maudsley Hospital, London, a Consultant Psychiatrist (attending)
and honorary Senior Lecturer. Dr. Tiller received her medical
degree from the Glasgow University Medical School, an M.B.A. from
Drexel University, and an MPhil from the University of
Pennsylvania.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-HT2c receptor superagonist, with negligible observed
impact on 5-HT2b and 5-HT2a receptor subtypes, in development for
the potential treatment of seizures associated with developmental
and epileptic encephalopathies. Longboard is also evaluating LP143,
a centrally acting, full CB2 receptor agonist, in development for
the potential treatment of neurodegenerative diseases associated
with neuroinflammation caused by microglial activation, and LP659,
a centrally acting, S1P receptor subtypes 1 and 5 modulator, in
development for the potential treatment of central nervous system
neuroinflammatory diseases.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
clinical and preclinical programs, ability to advance our pipeline
and develop medicines, attributes, building of our team, and focus.
For such statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024